Cover Image
Market Research Report

iBio, Inc. - Product Pipeline Review - 2016

Published by Global Markets Direct Product code 203716
Published Content info 47 Pages
Delivery time: 1-2 business days
Price
Back to Top
iBio, Inc. - Product Pipeline Review - 2016
Published: August 24, 2016 Content info: 47 Pages
Description

Summary:

Global Markets Direct's, 'iBio, Inc. - Product Pipeline Review - 2016', provides an overview of the iBio, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by iBio, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of iBio, Inc.
  • The report provides overview of iBio, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses iBio, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features iBio, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate iBio, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for iBio, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding iBio, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC08127CDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • iBio, Inc. Snapshot
    • iBio, Inc. Overview
    • Key Information
    • Key Facts
  • iBio, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • iBio, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • iBio, Inc. - Pipeline Products Glance
    • iBio, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • iBio, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • iBio, Inc. - Drug Profiles
    • anthrax vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HAI-05
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain A/H1N1] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • malaria vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NaAPR1M-74
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • anthrax + plague vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • human papillomavirus [Serotype 16] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IBIOCFB-03
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Anthrax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Neuraminidase for Influenza
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • palivizumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • yellow fever vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trypanosomiasis vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • iBio, Inc. - Pipeline Analysis
    • iBio, Inc. - Pipeline Products by Target
    • iBio, Inc. - Pipeline Products by Route of Administration
    • iBio, Inc. - Pipeline Products by Molecule Type
    • iBio, Inc. - Pipeline Products by Mechanism of Action
  • iBio, Inc. - Recent Pipeline Updates
  • iBio, Inc. - Dormant Projects
  • iBio, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • iBio, Inc., Key Information
  • iBio, Inc., Key Facts
  • iBio, Inc. - Pipeline by Indication, 2016
  • iBio, Inc. - Pipeline by Stage of Development, 2016
  • iBio, Inc. - Monotherapy Products in Pipeline, 2016
  • iBio, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • iBio, Inc. - Phase I, 2016
  • iBio, Inc. - Preclinical, 2016
  • iBio, Inc. - Discovery, 2016
  • iBio, Inc. - Pipeline by Target, 2016
  • iBio, Inc. - Pipeline by Route of Administration, 2016
  • iBio, Inc. - Pipeline by Molecule Type, 2016
  • iBio, Inc. - Pipeline Products by Mechanism of Action, 2016
  • iBio, Inc. - Recent Pipeline Updates, 2016
  • iBio, Inc. - Dormant Developmental Projects,2016

List of Figures

  • iBio, Inc. - Pipeline by Top 10 Indication, 2016
  • iBio, Inc. - Pipeline by Stage of Development, 2016
  • iBio, Inc. - Monotherapy Products in Pipeline, 2016
  • iBio, Inc. - Pipeline by Target, 2016
  • iBio, Inc. - Pipeline by Route of Administration, 2016
  • iBio, Inc. - Pipeline by Molecule Type, 2016
  • iBio, Inc. - Pipeline Products by Mechanism of Action, 2016
Back to Top